ABOUT PURPLEAI

Leading the Future of AI Stroke Care.

40+

Major Hospitals

World-Leading

AI Accuracy

FDA Cleared

Global Standard

2019

Established

purple ai title

The PurpleAI Story

Our Identity & Mission

PurpleAI is a medical AI company redefining acute stroke care — from faster detection to predictive foresight. Founded as an independent company in October 2024 after five years of R&D within SK Group, PurpleAI is deployed in numerous Korean university hospitals and expanding into the U.S. market with FDA-cleared technology. Our mission: give clinicians the speed, accuracy, and predictive insight they need to intervene earlier and improve patient outcomes in acute stroke care.

What We Build

Our Hyper Insight™ platform delivers FDA-cleared, real-time stroke detection in seconds. StrokeShieldAI™, our predictive analytics platform in development, forecasts high-risk complications during acute stroke care — before they manifest clinically.

Our Vision

Stroke care today is reactive. PurpleAI is building toward a future where it is predictive. By combining proven real-time triage with multimodal, data-driven risk modeling, we aim to shift the standard of care from detection-after-the-fact to anticipation-before-deterioration — enabling earlier intervention across the full continuum of acute neurovascular care. Detect Now. Predict What's Next.

Our Journey

Milestones

2019

R&D Start

  • Established SK C&C Digital Healthcare Team
  • Initiated R&D based on partnerships with medical institutions (Seoul National University Hospital, Ajou University Hospital)
2021

Obtained Regulatory Approvals from MFDS (Korea FDA)

  • Acquired Medical Device Manufacturing License
  • Obtained GMP Certification
  • Acquired Class III Medical Device Product Approvals
2022–Mid-2024

Market Entry & Competitive Validation

  • Secured over 10% market share in general hospitals in Korea
  • Designated as breakthrough medical device by the Ministry of Food & Drug Safety (MFDS)
  • Received U.S. FDA clearance
Mid-2024 onward

Establishment of PurpleAI for R&D: Predictive Stroke Care

  • Approved for venture spin-off and established PurpleAI Inc.
  • Acquired SK C&C's medical AI business
  • Raised Pre-A Round investment (totaling 2.5 billion KRW)